Trial Profile

A 6 month, open label, prospective, multi centre, international study of a transition to flexibly dose paliperidone palmitate (a second generation antipsychotic) in patients with schizophrenia previously unsuccessfully treated with oral or long acting injectable antipsychotics

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record and as per European Clinical Trials Database record, status is ongoing in Spain and UK and completed in remaining countries, hence status amended as per NCT.
16 Aug 2012 Actual patient number changed from 1046 to 1045 as reported by ClinicalTrials.gov.
07 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com